Alto Neuroscience develops clinical-stage precision medicines for neuropsychiatric disorders, using its Precision Psychiatry Platform™ to analyze EEG activity, neurocognitive assessments, wearable data and other biomarkers that may identify patient populations for its product candidates.
Company news centers on clinical data, trial initiations and pipeline decisions for programs including ALTO-207 in treatment-resistant depression and major depressive disorder, ALTO-101 in cognitive impairment associated with schizophrenia, and other candidates for bipolar depression, schizophrenia and mental health conditions. Updates also cover financial results, capital activity, regulatory designations, medical-meeting presentations and investor-conference participation.
Alto Neuroscience, Inc. ('Alto') (ANRO) announced upcoming data presentations at the Society of Biological Psychiatry and American Society of Clinical Psychopharmacology Annual Meetings, showcasing its precision psychiatry pipeline. The company highlighted neurobiological markers linked to cognitive impairment in schizophrenia and the development of novel compounds for depression and schizophrenia. The ALTO-100 study identified memory-based cognitive markers predicting antidepressant response, while ALTO-101 showed significant effects on electrophysiological measures relevant to cognitive processing. ALTO-300 demonstrated EEG-based cognitive markers predicting greater response. The presentations aim to contribute to the scientific community and further develop treatment options for patients.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.